What is Novavax's cash & equivalents?

Novavax (NVAX) reported cash & equivalents of $228.36M in Q1 2026.

How has Novavax's cash & equivalents changed year-over-year?

Novavax's cash & equivalents decreased by 13.3% year-over-year, from $263.34M to $228.36M.

What is the long-term trend for Novavax's cash & equivalents?

Over 5 years (2020 to 2025), Novavax's cash & equivalents has grown at a -15.3% compound annual growth rate (CAGR), from $553.4M to $240.63M.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Novavax NVAX Cash & Equivalents

Cash & Equivalents at other companies

ModernaMRNA

$1.91B+17.4%

Roivant SciencesROIV

$1.42B+1,411%

Merck & Co.MRK

$5.4B-38.2%

Vaxcyte, Inc.PCVX

$262.31M-24.7%

Viridian Therapeutics, Inc.VRDN

$176.35M+51.7%

ALN

Alnylam PharmaceuticalsALNY

$1.71B+67.5%

Other financials

Income statement

See full

Revenue$139.5M-79.1%

Gross profit$108.8M-83.3%

Operating income-$15.4M-103%

Net income-$9.5M-102%

EPS (diluted)-$0.06-102%

Balance sheet

See full

Total debt$295.1M+404%

Total equity-$144.8M-91.4%

Total assets$1.0B-19.3%

Cash flow

See full

Operating cash flow-$32.4M+82.5%

CapEx$1.3M-20.4%

Free cash flow-$33.7M+82.0%

Valuation

See full

Market cap$1.46B+28.6%

Enterprise value$1.53B+68.6%

P/S2.5×+1.5×

Profitability

See full

Gross margin85%-2.5pp

Operating margin-13.1%-45.9pp

Net margin-14.7%-52.9pp

FCF margin-58.9%-61.4pp

Returns & leverage

See full

Return on equity-238.6%—

Debt / equity1.5×—

Current ratio2.5×+0.4×

Where this comes from

Reported directly by Novavax in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Novavax’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Novavax's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Novavax's cash & equivalents?: Novavax (NVAX) reported cash & equivalents of $228.36M in Q1 2026.
How has Novavax's cash & equivalents changed year-over-year?: Novavax's cash & equivalents decreased by 13.3% year-over-year, from $263.34M to $228.36M.
What is the long-term trend for Novavax's cash & equivalents?: Over 5 years (2020 to 2025), Novavax's cash & equivalents has grown at a -15.3% compound annual growth rate (CAGR), from $553.4M to $240.63M.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.